Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

NCT00627588 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

BIOLOGICAL: ProSavin
BIOLOGICAL: ProSavin

Sponsor

Oxford BioMedica